WASHINGTON, D.C. – Jan. 24, 2023 – Nancy E. Taylor, co-chair of the Health Care & FDA Practice of global law firm Greenberg Traurig, LLP, will speak on the Food and Drug Law Institute’s (FDLI) Live Webinar Jan. 25 from 2:00-3:30 p.m.
The panel, titled “Implementation of the Inflation Reduction Act: Healthcare Reform and Implications for the Pharmaceutical Industry,” will discuss “the multi-faceted implications of the IRA on industry and the state of public health, as well as benefits and risks posed by implementing this framework, including impacts on prescription drug affordability, generic drugs, orphan drug exclusivity, differential treatment between small molecules and biologics, and strategy shifting for industry,” according to FDLI.
Taylor focuses her practice on health and FDA related matters. She has broad experience working with providers, plans, employers, private equity firms, and FDA regulated companies. She advises clients on health care transactions, health and FDA regulatory policy and compliance, and responding to Congressional and Administration investigations and audits. Prior to joining Greenberg Traurig, Taylor served 10 years as health policy director for a Senate committee and worked on numerous significant health and FDA laws. She also served as CEO of a startup medical device company, where she obtained eight product clearances, including securing reimbursement coverage for each product.